share_log

AbbVie | 10-Q: Q2 2024 Earnings Report

AbbVie | 10-Q: Q2 2024 Earnings Report

艾伯维公司 | 10-Q:2024财年二季报
美股SEC公告 ·  2024/08/08 03:01

Moomoo AI 已提取核心信息

AbbVie reported Q2 2024 global net revenues of $14.5 billion, increasing 4.3% year-over-year, with operating earnings of $4.0 billion and diluted EPS of $0.77. The growth was primarily driven by Skyrizi and Rinvoq, which saw revenues surge 44.8% and 55.8% respectively, helping offset a 29.8% decline in Humira sales due to biosimilar competition.The company completed its acquisition of ImmunoGen for $9.8 billion in February 2024, strengthening its oncology portfolio with Elahere which contributed $128 million in Q2 revenues. AbbVie issued $15 billion in senior notes to finance the ImmunoGen and Cerevel Therapeutics acquisitions. The gross margin improved to 71% from 69% in Q2 2023, benefiting from lower amortization of intangibles.Research and development expenses increased 12% to $1.9 billion as AbbVie continued investing in its pipeline. The company maintained its quarterly dividend at $1.55 per share and repurchased 5 million shares for $959 million during H1 2024. The effective tax rate was 36% for Q2 2024, up from 22% in Q2 2023, primarily due to business development activities.
AbbVie reported Q2 2024 global net revenues of $14.5 billion, increasing 4.3% year-over-year, with operating earnings of $4.0 billion and diluted EPS of $0.77. The growth was primarily driven by Skyrizi and Rinvoq, which saw revenues surge 44.8% and 55.8% respectively, helping offset a 29.8% decline in Humira sales due to biosimilar competition.The company completed its acquisition of ImmunoGen for $9.8 billion in February 2024, strengthening its oncology portfolio with Elahere which contributed $128 million in Q2 revenues. AbbVie issued $15 billion in senior notes to finance the ImmunoGen and Cerevel Therapeutics acquisitions. The gross margin improved to 71% from 69% in Q2 2023, benefiting from lower amortization of intangibles.Research and development expenses increased 12% to $1.9 billion as AbbVie continued investing in its pipeline. The company maintained its quarterly dividend at $1.55 per share and repurchased 5 million shares for $959 million during H1 2024. The effective tax rate was 36% for Q2 2024, up from 22% in Q2 2023, primarily due to business development activities.
艾伯维公司报告了2024年第二季度全球净收入为145亿美金,同比增长4.3%,经营收益为40亿美金,摊薄后每股收益为0.77美金。增长主要受到Skyrizi和Rinvoq的推动,它们的收入分别激增44.8%和55.8%,帮助抵消了因生物类似药竞争导致的Humira销售下降29.8%。该公司于2024年2月完成了对ImmunoGen的98亿美金收购,加强了其肿瘤学产品组合,其中Elahere在第二季度贡献了12800万美金的收入。艾伯维公司发行了150亿美金的高级票据,以融资ImmunoGen和Cerevel Therapeutics的收购。毛利率从2023年第二季度的69%提高至71%,受益于...展开全部
艾伯维公司报告了2024年第二季度全球净收入为145亿美金,同比增长4.3%,经营收益为40亿美金,摊薄后每股收益为0.77美金。增长主要受到Skyrizi和Rinvoq的推动,它们的收入分别激增44.8%和55.8%,帮助抵消了因生物类似药竞争导致的Humira销售下降29.8%。该公司于2024年2月完成了对ImmunoGen的98亿美金收购,加强了其肿瘤学产品组合,其中Elahere在第二季度贡献了12800万美金的收入。艾伯维公司发行了150亿美金的高级票据,以融资ImmunoGen和Cerevel Therapeutics的收购。毛利率从2023年第二季度的69%提高至71%,受益于无形资产的摊销减少。研究和开发支出增加了12%,达到19亿美金,因为艾伯维公司继续投资于其产品管道。该公司将季度股息维持在每股1.55美金,并在2024年上半年以95900万美金回购了500万股。2024年第二季度的有效税率为36%,高于2023年第二季度的22%,主要由于业务发展活动。
声明:本内容仅用作提供资讯及教育之目的,不构成对任何特定投资或投资策略的推荐或认可。 更多信息